
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Beijing Biostar Pharmaceuticals Co., Ltd.**, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

SUPPLEMENTAL CIRCULAR

**(1) CLARIFICATION AND WITHDRAWAL OF ORDINARY RESOLUTION
IN RELATION TO THE CONNECTED TRANSACTION;**

(2) PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026;

**(3) WITHDRAWAL OF SPECIAL RESOLUTIONS IN RELATION TO
SHARE OPTION SCHEME;**

AND

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

This supplemental circular should be read in conjunction with the circular of the Company dated 28 May 2026.

A supplemental notice convening the AGM of the Company to be held at 1202B, 12/F, Building 3, No. 22 Ronghua Middle Road, Beijing Economic-Technological Development Area, Beijing, PRC on Friday, 26 June 2026 at 3:00 p.m. is set out in this supplemental circular.

No revised form of proxy will be issued by the Company. Whether or not you are able to attend the AGM, please complete and sign the original form of proxy (the "**Original Proxy Form**") previously dispatched to you in accordance with the instructions printed thereon and return it to the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not less than 24 hours before the time appointed for the holding of the AGM (i.e. not later than 3:00 p.m. on Thursday, 25 June 2026) or any adjournment thereof.

References to time and dates in this circular are to Hong Kong time and dates.

11 June 2026

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
INTRODUCTION	4
CLARIFICATION AND WITHDRAWAL OF ORDINARY RESOLUTION IN RELATION TO THE CONNECTED TRANSACTION	4
PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026	4
WITHDRAWAL OF SPECIAL RESOLUTIONS IN RELATION TO SHARE OPTION SCHEME	5
ARRANGEMENTS REGARDING THE PROXY FORM	5
RESPONSIBILITY STATEMENT	6
SUPPLEMENTAL NOTICE OF AGM	7

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

“2025 Annual Report”	The annual report published by the Company on 28 April 2026
“AGM”	the annual general meeting of the Company to be held at 1202B, 12/F, Building 3, No. 22 Ronghua Middle Road, Beijing Economic-Technological Development Area, Beijing, PRC on Friday, 26 June 2026 at 3:00 p.m.
“Board” or “Board of Directors”	the board of directors of the Company
“Business Day(s)”	any day on which securities are traded on the Stock Exchange
“Company”	Beijing Biostar Pharmaceuticals Co., Ltd. (北京華昊中天生物醫藥股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (Stock Code: 2563)
“Director(s)”	the director(s) of the Company
“Directors’ Report”	Directors’ Report in the 2025 Annual Report
“Group”	the Company and its subsidiaries from time to time
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Hong Kong dollars” or “HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“H Share(s)”	overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, which are listed on the Stock Exchange and traded in Hong Kong dollars
“H Share Registrar”	Computershare Hong Kong Investor Services Limited
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“Original Circular”	the Company’s AGM circular dated 28 May 2026
“Original Notice”	notice of AGM published by the Company dated 28 May 2026
“Original Proxy Form”	proxy form provided by the Company dated 28 May 2026

DEFINITIONS

“Share Option Scheme”	the share option scheme proposed for adoption by the Company at the AGM, in its present or any amended form
“Shareholders”	holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited



Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

Executive Directors:

Dr. Tang Li (Tang Li博士)

*(Chairperson, Executive Director,
Chief Scientific Officer and
Chief Marketing Officer)*

Dr. Qiu Rongguo (Qiu Rongguo博士)

Mr. Zhang Cheng (張成先生)

Dr. Guan Jin (關津博士)

Non-executive Directors:

Mr. Tang Jin (唐進先生)

Ms. Dai Xuefen (戴雪芬女士)

Independent Non-executive Directors:

Mr. Shiu Shu Ming (蕭恕明先生)

Dr. Ye Chengang (葉陳剛博士)

Registered Office:

1202B, 12/F, Building 3

No. 22 Ronghua Middle Road

Beijing Economic-Technological

Development Area,

Beijing, PRC

*Head Office and Principal Place of
Business in the PRC:*

1202B, 12/F, Building 3

No. 22 Ronghua Middle Road

Beijing Economic-Technological

Development Area

Beijing, PRC

Principal Place of Business in Hong Kong:

Unit 02, 8/F,

Tung Che Commercial Centre

246 Des Voeux Road West

Hong Kong

11 June 2026

To the Shareholders

Dear Sir or Madam,

SUPPLEMENTAL CIRCULAR

**(1) CLARIFICATION AND WITHDRAWAL OF ORDINARY RESOLUTION
IN RELATION TO THE CONNECTED TRANSACTION;**

(2) PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026;

**(3) WITHDRAWAL OF SPECIAL RESOLUTIONS IN RELATION TO
SHARE OPTION SCHEME;**

AND

SUPPLEMENTAL NOTICE OF THE ANNUAL GENERAL MEETING

LETTER FROM THE BOARD

I. INTRODUCTION

References are made to the Original Circular and the Original Notice. The purpose of this supplemental circular is to provide you with further details regarding (i) the withdrawal of ordinary resolution in relation to the connected transaction; (ii) provision of supplemental information on proposed re-appointment of auditor for 2026; and (iii) the withdrawal of special resolutions in relation to the Share Option Scheme.

II. CLARIFICATION AND WITHDRAWAL OF ORDINARY RESOLUTION IN RELATION TO THE CONNECTED TRANSACTION

The Board clarifies to the shareholders that an ordinary resolution to ratify the Group's 2025 connected transactions (the "**Ordinary Resolution**", originally numbered as resolution no. 7 in the Original Notice) was inadvertently included in the Original Circular and the Original Notice.

The inclusion of the Ordinary Resolution was a pure typographical error and an inadvertent clerical oversight during the drafting process. The Company hereby clarifies that:

- During the 2025 financial year, the Group conducted a procurement transaction with Beijing Baygen Technology Co., Ltd. amounting to RMB2,668,922.75.
- As all the applicable size tests under Chapter 14A of the Listing Rules in respect of such transaction were well below the 5% threshold, the transaction constitutes a fully exempt connected transaction which is entirely exempt from the independent shareholders' approval requirement under Rule 14A.76.
- The statement in the Directors' Report in the 2025 Annual Report that the Group did not conduct any non-exempt connected transactions remains valid and accurate in all material respects.

As the underlying transaction is fully exempt from Shareholders' approval, no resolution is legally required to be proposed. To rectify this drafting error, the Board has formally resolved to withdraw the subject resolution. It will not be put forward or voted upon at the AGM.

III. PROPOSED RE-APPOINTMENT OF AUDITOR FOR 2026

The Board wishes to provide further information that having considered factors including the business situation of the Group, the expected audit scope, the audit timetable and the auditors' resources, the audit fees shall not exceed RMB1.48 million, and the Board is authorized to determine the specific remuneration.

LETTER FROM THE BOARD

IV. WITHDRAWAL OF SPECIAL RESOLUTIONS IN RELATION TO SHARE OPTION SCHEME

The Board announces that special resolution nos. 14 and 15 as set out in the Original Notice in relation to the adoption of the Share Option Scheme (the “**Special Resolutions**”) will be withdrawn and will not be put forward for consideration and voting by the Shareholders at the AGM.

Reason for the Withdrawal

For the purpose of refining the terms of the Share Option Scheme, the Board has decided to withdraw the Special Resolutions at the current stage.

The Board considers that the withdrawal of the Special Resolutions does not have any material adverse impact on the business operations or financial position of the Company and its subsidiaries.

After refinement of the Share Option Scheme, it will be proposed for voting at a subsequent Shareholders’ meeting.

V. ARRANGEMENTS REGARDING THE PROXY FORM

Due to the withdrawal of the Ordinary Resolution and Special Resolutions, the voting arrangements at the AGM will be affected as follows:

- (a) **No Voting:** No vote will be cast, and no votes will be counted, in respect of the Ordinary Resolution and Special Resolutions at the AGM.
- (b) **Validity of Other Resolutions:** Those resolutions (other than the Ordinary Resolution and Special Resolutions) as set out in the Original Notice remain valid and will be voted upon at the AGM.
- (c) **Status of the Original Proxy Form:** Shareholders are not required to re-submit a new proxy form solely due to the withdrawal of the Ordinary Resolution and Special Resolutions, as the remaining votes cast on other resolutions will still be processed.

Save for the withdrawal of the Ordinary Resolution and Special Resolutions and the supplementary information on auditors’ remuneration as disclosed in the supplementary circular dated 11 June 2026, all information and contents set out in the Original Circular, the Original Notice, and the Original Proxy Form remain unchanged.

LETTER FROM THE BOARD

VI. RESPONSIBILITY STATEMENT

This supplemental circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this supplemental circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this supplemental circular misleading.

Yours faithfully,

By order of the Board

Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

Dr. Tang Li

Chairperson and Executive Director



Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

NOTICE OF ANNUAL GENERAL MEETING

Reference is made to the notice of annual general meeting (the “**Original Notice**”) of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) will be convened and held at 1202B, 12/F, Building 3, No. 22 Ronghua Middle Road, Beijing Economic-Technological Development Area, Beijing, PRC on Friday, 26 June 2026 at 3:00 p.m. (the “**AGM**”) and this supplemental notice shall be read together with the Original Notice. Unless otherwise specified, capitalised terms used herein shall have the same meanings as those defined in the Original Notice and the supplemental circular of the Company dated 11 June 2026 (the “**Supplemental Circular**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN THAT:

Due to the matters as set out in the Supplemental Circular, the resolutions under items numbered 7, 14 and 15 in the Original Notice have been withdrawn and will not be submitted to the AGM for approval by the Shareholders.

Apart from the amendments set out above, all information contained in the Original Notice shall remain to have full force and effect.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, 11 June 2026

SUPPLEMENTAL NOTICE OF AGM

Notes:

1. Details of the resolutions stated above are set out in the Supplemental Circular. No revised form of proxy will be issued by the Company.
2. Apart from the withdrawal of the Ordinary Resolution and Special Resolutions and other information as set out in the Supplemental Circular, all other matters to be dealt with at the AGM remain unchanged. For details of the other resolutions to be considered and approved at the AGM, eligibility for attending/voting at the AGM, closure of register of members of the Company and other relevant matters, please refer to the circular of the Company dated 28 May 2026 and the Original Notice.

As at the date of this circular, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.